BioSpace News Archive

Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the 3rd Global NASH Congress 2020 at the London Heathrow Marriott on Tuesday, February 11, at 3:00 p.m. (15:00) local time.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, today announced the publication of a scientific paper entitled, “The Novel Reversible LSD1 Inhibitor SP-2577 Promotes Anti-Tumor Immunity in SWItch/Sucrose-NonFermentable (SWI/SNF)1,” available in preprint at bioRxiv.com.

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company donated RMB1 million worth of their most popular immune system boosting products to Shunchang General Hospital.

Next major milestone in Mino-Lok trial is the 75% interim analysis for superior efficacy and is expected in first half of 2020

Urovant Sciences announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two double-blind, placebo-controlled randomized Phase 1 trials.

VirTrial announced its international expansion with a newly appointed International Director of Business Development, a network of virtual trial capable research sites across 31 countries, policies supporting GDPR compliance, and product enhancements that support language translation into any left to right reading language.

Biotech Showcase, the investor conference driving therapeutic innovation, advances in digital medicine, and broad industry collaboration, had more than 3,800 attendees, marking rising participation every year since the first meeting 12 years ago.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that CEO Nadav Kidron will present a company overview at the BIO CEO & Investor Conference in New York City.

OncoSec Medical Incorporated, a company developing late-stage intratumoral cancer immunotherapies, announced the publication of data showing that TAVO™ treatment, administered through OncoSec’s electroporation gene delivery system, resulted in regression of injected and non-injected Merkel cell carcinoma tumors.

At present, there is an outbreak of SARS virus called novel coronavirus 2020 going in China.